TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23531317

Group type: EXPERIMENTAL
Intervention: Diesel Exhaust (DE) exposure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Filtered Air (FA) exposure
Number of subjects: 32
Study: 21501479

Group type: EXPERIMENTAL
Intervention: Training programme for young cannabis users (CAN Stop)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 19352186

Group type: EXPERIMENTAL
Intervention: Endoflex endotracheal tube for oral intubation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endoflex endotracheal tube for nasal intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional endotracheal tube with stylet for oral intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional endotracheal tube for nasal intubation
Number of subjects: 60
Study: 16756423

Group type: EXPERIMENTAL
Intervention: 20 mg diazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15536765

Group type: EXPERIMENTAL
Intervention: Alcohol with high thujone concentration
Number of subjects: 25

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Alcohol with low thujone concentration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High thujone concentration
Number of subjects: 25
Study: 10839290

Group type: EXPERIMENTAL
Intervention: BW12C and MMC
Number of subjects: 17
Study: 9405961

Group type: EXPERIMENTAL
Intervention: tianeptine (37.5 mg/day)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: imipramine (150 mg/day)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: tianeptine (75 mg/day)
Number of subjects: 556

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 556
Study: 8403764

Group type: EXPERIMENTAL
Intervention: Bolus chasing technique
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional stepped technique
Number of subjects: 116
Study: 2876005

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (50 micrograms sc bolus before meals)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (standardized mixed meals without SMS 201-995)
Number of subjects: 6
Study: 29753704

Group type: EXPERIMENTAL
Intervention: Kinesiotherapy/auriculotherapy group (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Kinesiotherapy group (n = 11)
Number of subjects: 22
Study: 27315293

Group type: EXPERIMENTAL
Intervention: INTACS-SK (Intacs, Addition Technology, Inc.)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: KeraRing SI6 (Mediaphacos Ltda.)
Number of subjects: 69
Study: 24469436

Group type: EXPERIMENTAL
Intervention: Oesophageal cooling with ice water (5 mL injected prior to RF energy delivery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (oesophageal cooling not applied)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oesophageal cooling with ice water
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 22279570

Group type: EXPERIMENTAL
Intervention: Circulating Angiopoietin-2 (Ang-2) levels during active AAV
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Circulating Angiopoietin-2 (Ang-2) levels during remission
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Correlation of Ang-2 with BVAS/WG score
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Correlation of Ang-2 with markers of systemic inflammation
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Correlation of Ang-2 with renal function
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ang-2 levels in patients with glomerulonephritis
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ang-2 levels in newly diagnosed AAV patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ang-2 levels in patients recently started on treatment
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Predictive value of Ang-2 levels during active disease
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Predictive value of Ang-2 levels in remission
Number of subjects: 162
Study: 19684105

Group type: EXPERIMENTAL
Intervention: Standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
Number of subjects: 380
Study: 19013285

Group type: EXPERIMENTAL
Intervention: Strawberry supplementation (454 g/d, 112 kcal)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oat bran bread (control, 65 g/d, 112 kcal, approximately 2 g beta-glucan)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Strawberry supplementation
Number of subjects: 28
Study: 15809481

Group type: COMPARATOR
Intervention: Setup A (standard PET head holder with no support at the sides)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Setup B (special head holder fitted with a subject-specific mold from construction foam)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Setup C (vacuum-lock bag)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Setup D (special head holder fitted with a vacuum-lock bag)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Setup C in clinical PET/CT
Number of subjects: 51
Study: 12867883

Group type: EXPERIMENTAL
Intervention: PGE-1
Number of subjects: 123

Group type: COMPARATOR
Intervention: pentoxyfillin-buflomedil
Number of subjects: 123
Study: 9862876

Group type: EXPERIMENTAL
Intervention: Interferon therapy for chronic hepatitis C (24 weeks duration)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Sustained viral response to interferon therapy (n = 41)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Sustained biochemical responses to interferon therapy
Number of subjects: 642

Group type: COMPARATOR
Intervention: Healthy controls (n = 750)
Number of subjects: 642
Study: 8571994

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises for 3 months
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises for 3 months (completed treatment)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises with audiotape
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (6 months follow-up)
Number of subjects: 71
Study: 1677698

Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine
Number of subjects: 668

Group type: COMPARATOR
Intervention: 70% alcohol
Number of subjects: 668

Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 668

Group type: COMPARATOR
Intervention: Infusion-related bacteraemias
Number of subjects: 668
Study: 6837487

Group type: EXPERIMENTAL
Intervention: Exercise (jogging for 20 to 50 min/day for 6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sedentary living (no exercise for 6 weeks)
Number of subjects: 12
Study: 31039786

Group type: EXPERIMENTAL
Intervention: Self-help app for one month
Number of subjects: 234

Group type: COMPARATOR
Intervention: Psychoeducational reading material (brochure)
Number of subjects: 234
Study: 29367116

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Noncontingent reinforcement (NR)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Increased drinking during the Initial Phase
Number of subjects: 110
Study: 26996450

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy for six weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonphysiotherapy group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 24628830

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 30
Study: 22094531

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 21119316

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 17966977

Group type: COMPARATOR
Intervention: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 710 mg or 1420 mg per day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 1000 mg per day
Number of subjects: 64
Study: 14981375

Group type: EXPERIMENTAL
Intervention: Metronidazole (two 2-g doses, 48 hours apart)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1341
Study: 12411539

Group type: EXPERIMENTAL
Intervention: Lactate clamp (LC) procedure with exogenous lactate infusion clamped at approximately 4 mM during exercise at 55% V(O2,peak)
Number of subjects: 0
Study: 9820381

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (OAC)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (AC)
Number of subjects: 507
Study: 7644398

Group type: EXPERIMENTAL
Intervention: Antituberculosis treatment regimen including pyrazinamide, isoniazid, and rifampicin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 2755692

Group type: EXPERIMENTAL
Intervention: Roth's sealer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CRCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nogenol sealer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no sealer)
Number of subjects: 60
Study: 806396

Group type: EXPERIMENTAL
Intervention: 2% solution of sodium cromoglycate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30343388

Group type: EXPERIMENTAL
Intervention: PLA2G16 SNPs (rs11600655, rs3809072, rs3809073, rs640908, rs66475048)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Haplotypes (CTC and GGA) of rs11600655, rs3809073, and rs3809072
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: rs11600655 polymorphism
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: rs3809073 and rs3809072
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: rs11600655 CC, rs640908 CT, and rs66475048 GA genotypes
Number of subjects: 498
Study: 27218216

Group type: EXPERIMENTAL
Intervention: Serum IGF‐1
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serum TNF‐alpha
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Serum VEGF165
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 108
Study: 25138123

Group type: EXPERIMENTAL
Intervention: Exercise training program (50‐60 min aerobic, strengthening and stretching exercise, 3 days a week, for 12 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No training program at all (control group)
Number of subjects: 37
Study: 23246533

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21419674

Group type: EXPERIMENTAL
Intervention: Hypocaloric low-fat diet
Number of subjects: 24
Study: 18469662

Group type: EXPERIMENTAL
Intervention: 0.01% lidocaine solution (10 mL of 1% lidocaine in 1 L saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study: 16546756

Group type: COMPARATOR
Intervention: Caregivers of ALS patients rated premorbid personality traits using the NEO-Personality Inventory.
Number of subjects: 0
Study: 11323346

Group type: EXPERIMENTAL
Intervention: Rapacuronium (RAP) 1.5 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vecuronium (VEC) 0.1 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Succinylcholine (SUC) 1 mg/kg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after RAP
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after VEC
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after SUC
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (VEC) after RAP
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (VEC) after VEC
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (VEC) after SUC
Number of subjects: 3
Study: 9182212

Group type: EXPERIMENTAL
Intervention: Abciximab with low-dose heparin (initial bolus of 70 U per kilogram)
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Abciximab with standard-dose heparin (initial bolus of 100 U per kilogram)
Number of subjects: 2792

Group type: COMPARATOR
Intervention: Placebo with standard-dose heparin (initial bolus of 100 U per kilogram)
Number of subjects: 2792
Study: 7894540

Group type: EXPERIMENTAL
Intervention: Zolpidem (therapeutic doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal conditions (no specific intervention mentioned)
Number of subjects: 0
Study: 3675133

Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of ethanol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.1 mL/kg of ethanol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31603281

Group type: EXPERIMENTAL
Intervention: Soya lecithin (1.5 g per day) in a custom-made biscuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29222809

Group type: EXPERIMENTAL
Intervention: 1 mm abutment
Number of subjects: 22

Group type: COMPARATOR
Intervention: 3 mm abutment
Number of subjects: 22
Study: 28551778

Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 5928
Study: 25673440

Group type: EXPERIMENTAL
Intervention: Kuntai capsule (4 capsules tid, po for 12 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg qd, po for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Blank Control (no drug addition)
Number of subjects: 90
Study: 23987657

Group type: EXPERIMENTAL
Intervention: Online palliative care education
Number of subjects: 169

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 169
Study: 20888993

Group type: EXPERIMENTAL
Intervention: Early treatment (chemotherapy started within 28 days of increased CA125 measurement)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Delayed treatment (chemotherapy commenced at clinical or symptomatic relapse)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Overall survival (primary outcome)
Number of subjects: 529
Study: 18172907

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Venlafaxine IR (75 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16955451

Group type: EXPERIMENTAL
Intervention: Qigong practice for 16 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Newspaper reading group for 16 weeks
Number of subjects: 82
Study: 12714152

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 76

Group type: COMPARATOR
Intervention: Inactive pacing (sinus rhythm group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ventricular-inhibited pacing (atrial fibrillation group)
Number of subjects: 76
Study: 10939428

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with PEM regimen: cisplatin 60 mg/m2, etoposide 40 mg/m2, mitomycin-C 7 mg/m2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 32
Study: 8755686

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg, once daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 1584996

Group type: EXPERIMENTAL
Intervention: 100 mg of mifepristone (RU 486)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3937189

Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin with Ethambutol
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin with Pyrazinamide
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifampicin without a third drug
Number of subjects: 513

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 513
Study: 29704965

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training Group (DBT‐ST)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Activities‐Based Support Group (ASG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both DBT‐ST and ASG
Number of subjects: 44
Study: 27445162

Group type: EXPERIMENTAL
Intervention: Carbamylated albumin concentration measurement at dialysis initiation and every subsequent 90-day period until 1 year or death
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Carbamylated albumin concentration modeling for mortality prediction
Number of subjects: 366
Study: 25443605

Group type: EXPERIMENTAL
Intervention: Risk scoring model developed from identified risk factors (amount of contrast, diabetes with microangiopathy, hypotension, peripheral vascular disease, albuminuria, glomerular filtration rate (GFR), anemia)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Risk scoring model
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 1200
Study: 22111654

Group type: EXPERIMENTAL
Intervention: Preventive maintenance (GTP; n = 39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No preventive maintenance (GNTP; n = 41)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Global sample
Number of subjects: 80
Study: 20728709

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study: 18182617

Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Control arms (sequential control: four cycles of doxorubicin at 75 mg/m2, followed by three cycles of CMF; concurrent control: four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Docetaxel treatment (both sequential and concurrent)
Number of subjects: 2887
Study: 15794970

Group type: EXPERIMENTAL
Intervention: Hip spica group
Number of subjects: 108

Group type: COMPARATOR
Intervention: External fixation group
Number of subjects: 108
Study: 11911510

Group type: EXPERIMENTAL
Intervention: Professionally guided self-care programme
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study: 10407836

Group type: EXPERIMENTAL
Intervention: First episode schizophrenia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 66
Study: 7478682

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (30 micrograms/h)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 2331957

Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg four times a day
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cimetidine, 400 mg four times a day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cisapride and Cimetidine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 73
Study: 95715

Group type: EXPERIMENTAL
Intervention: Bilateral finger movements
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unilateral right-sided finger movements
Number of subjects: 19
Study: 31799782

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30783794

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Chlorpromazine 25 mg
Number of subjects: 4
Study: 28625962

Group type: EXPERIMENTAL
Intervention: Nerve Sparing Radical Hysterectomy (NSRH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Radical Hysterectomy (CRH)
Number of subjects: 30
Study: 25016597

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (3.05 g/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Typical Australian diet (23.7 g/day)
Number of subjects: 33
Study: 22944373

Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 22013171

Group type: EXPERIMENTAL
Intervention: Higher genetic risk results counseling intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower genetic risk results counseling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untested controls
Number of subjects: 0
Study: 19462696

Group type: EXPERIMENTAL
Intervention: NYHA class III-IV patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) and Depression measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive functioning measures
Number of subjects: 0
Study: 17925871

Group type: EXPERIMENTAL
Intervention: SP+AS+PQ (0.75 mg/kg primaquine)
Number of subjects: 108

Group type: COMPARATOR
Intervention: SP+AS
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SP+AS+PQ
Number of subjects: 108
Study: 10849921

Group type: EXPERIMENTAL
Intervention: Active feedback via practice visits from the pharmaceutical prescribing adviser
Number of subjects: 66

Group type: COMPARATOR
Intervention: Passive feedback via practice specific prescribing analysis workbook
Number of subjects: 66

Group type: COMPARATOR
Intervention: Reference group (no feedback)
Number of subjects: 66
Study: 8973990

Group type: EXPERIMENTAL
Intervention: Metformin HCL 1,700 mg (single dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metformin HCL 850 mg (multiple doses, 3 times daily for 19 doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metformin HCL (single and multiple doses) in healthy subjects
Number of subjects: 18